Diabetes treating compound medicine for reducing side effect of rosiglitazone and preparation method thereof

A technology of rosiglitazone and side effects, which is applied in the field of compound medicine for treating diabetes and its preparation, and can solve the problems of rosiglitazone with large side effects

Inactive Publication Date: 2013-08-21
罗国安
View PDF3 Cites 3 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0005] Based on the above-mentioned problems in the prior art, the present invention provides a compound drug for treating diabetes that reduces the side effects of rosiglitazon

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Diabetes treating compound medicine for reducing side effect of rosiglitazone and preparation method thereof
  • Diabetes treating compound medicine for reducing side effect of rosiglitazone and preparation method thereof
  • Diabetes treating compound medicine for reducing side effect of rosiglitazone and preparation method thereof

Examples

Experimental program
Comparison scheme
Effect test

preparation example Construction

[0020] The preparation method of the above-mentioned compound drug for treating diabetes that reduces the side effect of rosiglitazone specifically includes the following steps:

[0021] Screen drug candidates:

[0022] According to the side effect of rosiglitazone, the network screening model of side effect-pathway-candidate drug is constructed, and the candidate drug determined to eliminate the side effect of rosiglitazone is a diuretic drug, wherein the diuretic drug is spironolactone, amiloride, Any one of compound amiloride, ergosterol, triamterene, ethacrynic acid, hydrofluoromethylthiazide, and bumetanide, wherein compound amiloride is composed of the combination of amiloride and hydrochlorothiazide The mass ratio is 1:1 composition;

[0023] The rosiglitazone and the diuretic drug are prepared in a weight ratio of 1:0.04-1 to prepare a compound drug for treating diabetes (ie, a compound drug for rosiglitazone).

[0024] In the above method, constructing a network scr...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention discloses a diabetes treating compound medicine for reducing side effect of rosiglitazone and a preparation method thereof, and belongs to the field of medicine preparation. The compound medicine consists of rosiglitazone and a diuretic medicine, wherein the ratio of rosiglitazone to the diuretic medicine by weight is 1:(0.04-1). The diabetes treating compound medicine is compounded and matched with any one of spirolactone, amiloride, compound amiloride, ergosterol, triamterene, ethacrynic acid, hydroflumethiazide and bumetanide which can better eliminate side effect of rosiglitazone with rosiglitazone so as to form the compound medicine which not only can reduce the side effect of rosiglitazone, but also better treats diabetes.

Description

technical field [0001] The invention relates to the field of medicine, in particular to a compound medicine for treating diabetes and a preparation method thereof for reducing the side effect of rosiglitazone. Background technique [0002] Rosiglitazone (also known as Avandia) is a thiazolidinediones (TZDs) drug that can effectively treat type 2 diabetes. Currently, rosiglitazone is the only TZD drug that can be used alone in clinical practice, and it can also be used in combination with metformin. In September 2010, rosiglitazone was included in the "blacklist" by the European Food and Drug Administration due to its possible risk of cardiovascular disease, and it was not allowed to be re-marketed. Subsequently, my country's Food and Drug Administration and the Ministry of Health issued a joint notice stating that under the premise of "strengthening management", 12 types of rosiglitazone and its compound preparations, including this drug, can continue to be used conditional...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K45/00A61P3/10A61P7/10G06F19/12A61K31/4439
CPCA61K31/12A61K31/4965A61P3/10A61P7/10A61P13/12
Inventor 罗国安王义明
Owner 罗国安
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap